Longeveron
$2.27
19
-$0.1-4.22% Friday 21:00
Statistics
Day High
2.37
Day Low
2.25
52W High
4.58
52W Low
1.5
Volume
46,300
Avg. Volume
70,823
Mkt Cap
20.19M
P/E Ratio
-2.32
Dividend Yield
-
Dividend
-
Upcoming
Earnings
8MarExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.27
-0.18
-0.09
0
Expected EPS
-0.21
Actual EPS
0
People Also Follow
This list is based on the watchlists of people on Stock Events who follow LGVN. It's not an investment recommendation.
Analyst Ratings
6$Average Price Target
The highest estimate is $6.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Show more...
CEO
Employees
18
Country
US
ISIN
US54303L1044